Ruxolitinib
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4108 publications
Modulation of the sensitivity to ruxolitinib-mediated JAK2 inhibition by mutationally activated SHP2 exhibits cell context dependency in pre-clinical models of myeloproliferative neoplasms.
Journal: bioRxiv : the preprint server for biology
Published: October 23, 2026
Clinical improvement of necrobiosis lipoidica with topical ruxolitinib.
Journal: JAAD case reports
Published: October 22, 2026
Reply to 'Summer initiation of ruxolitinib in vitiligo: natural phototherapy confounds the seasonal signal'.
Journal: The British journal of dermatology
Published: October 21, 2026
Facial discoid dermatosis successfully treated with topical ruxolitinib: A case report.
Journal: JAAD case reports
Published: October 18, 2026
Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies.
Journal: Leukemia & lymphoma
Published: October 07, 2026
Janus kinase inhibitors in the management of lichen planus: a systematic review.
Journal: Annals of medicine
Published: October 07, 2026
Merkel cell carcinoma in a patient on ruxolitinib treatment for polycythemia vera.
Journal: JAAD case reports
Published: October 06, 2026
Topical ruxolitinib for prebullous phase of immune checkpoint Inhibitor-Induced bullous pemphigoid.
Journal: JAAD case reports
Published: October 02, 2026
Trial-derived body surface area rules may restrict access to topical precision therapies in vitiligo.
Journal: JAAD international
Published: October 02, 2026
Age-associated Autoimmunity Driven by T cell Immunosenescence.
Journal: bioRxiv : the preprint server for biology
Published: October 01, 2026
Emerging Topical Therapies and Skin Care Management for Hidradenitis Suppurativa.
Journal: Skin therapy letter
Published: September 28, 2026
Last Updated: 11/08/2026